Supplementary Material for: eGFR Slope Predicts Survival and Renal Outcomes in Myeloperoxidase-Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis: Development and Validation of a Pathogen-Free Model

Objectives: This study explores the potential of estimated glomerular filtration rate (eGFR) slope as a noninvasive marker for predicting renal survival and patient survival in myeloperoxidase (MPO) -antineutrophil cytoplasmic antibody (ANCA) -associated glomerulonephritis (AAGN) Methods: 377 MPO-AAGN patients were included. Kaplan-Meier and Cox regression analyses were performed to assess the predictive value of eGFR slopes for renal survival and patient survival. Then the models were validated by discrimination, calibration, and decision curve analysis. Results: The eGFR slope (calculated using a linear mixed-effects model with baseline and follow-up eGFR values up to defined timepoints), higher with better renal recovery, had a median of 2.54 (IQR: 0.49–6.02) ml/min/1.73m²/month for 3 months and 1.90 (IQR: -0.07–4.76) ml/min/1.73m²/month for one year. Multivariate Cox regression identified baseline eGFR (HR=0.96, 95% CI 0.95–0.98, P